Gencor received four approved claims from Health Canada for its standardized fenugreek extract called Libifem.
Photo © iStockphoto.com/PicturePartners
Gencor (Irvine, CA) received four approved claims from Health Canada for its standardized fenugreek extract called Libifem. The claims, based on clinical data include:
• Helps increase women’s sexual desire
• Helps support women’s healthy sex drive and libido
• Helps promote women’s sexual arousal
• May help reduce menopausal symptoms such as hot flashes and night sweats
"Receiving all four health claims further validates our research on Libifem and its ability to help reduce menopausal symptoms and promote healthy sexual activity," said Chase Shryoc, Gencor's vice president of sales and business development, in a press release. "Libifem is proving to be a well-rounded ingredient for women. We are currently conducting clinical trials to see its potential benefits for women in sports nutrition applications."
Libifem is GRAS and can be easily incorporated into a number of applications, including powders, tablets, and capsules. The new claims are only approved for use in Canada.
Kratom sees impressive sales growth despite its regulatory status and stigma
March 12th 2025Despite its controversy, kratom is a top-selling ingredient that consumers see value in. That said, brands need to work hard to demonstrate safety and quality of kratom products in the absence of legal regulatory status. Will kratom be able to overcome its stigma for even more growth and consumer acceptance?
DOJ asks Utah court to dismiss FTC lawsuit against Xlear Inc.
March 11th 2025On March 10, the DOJ and the defendant filed a stipulation to dismiss with prejudice the lawsuit in which each party agrees “to be responsible for its own costs and fees and agrees that no party shall be responsible to any other party for any fines, costs, fees, or penalties arising from this case.”
HHS announces efforts to eliminate independent conclusion of GRAS
Published: March 11th 2025 | Updated: March 11th 2025U.S. Department of Health and Human Services (HHS) Secretary, Robert F. Kennedy Jr., is directing the acting U.S. Food and Drug Administration’s (FDA) acting commissioner to explore rulemaking that would eliminate the independent conclusion of GRAS provision.